Rocuronium is a muscle relaxant used during surgery and medical procedures to paralyze muscles, making it easier for doctors to perform operations and manage patients on breathing machines.[2] Esmeron is currently approved and in use across 37 indications[4].[1]
Esmeron is one of 536 small molecule programs targeting Hysterectomy. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
348 competitors in Prostate Cancer
Esmeron
Androgen Deprivation Therapy
Lipitor
Acetylsalicylic Acid
Lhrha
Piflufolastat
AAA817
Florastamin
Trexall
Botox
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Mar 17, 1994
ZEMURON
NDA NDA020214
Jun 9, 2025
ROCURONIUM BROMIDE
NDA NDA217472
Oct 24, 2025
ROCURONIUM BROMIDE
NDA NDA219108
Sources
Details
Patent Cliff
Jul 22, 2039
Earliest patent expiration — generic entry possible after this date